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BACKGROUND: Familial nervous system cancers are rare and limited data on familial aspects are available particularly on site-specific
tumours.
METHODS: Data from five Nordic countries were used to analyse familial risks of nervous system tumours. Standardised incidence
ratios (SIRs) were calculated for offspring of affected relatives compared with offspring of non-affected relatives.
RESULTS: The total number of patients with nervous system tumour was 63307, of whom 32347 belonged to the offspring generation.
Of 851 familial patients (2.6%) in the offspring generation, 42 (4.7%) belonged to the families of a parent and at least two siblings
affected. The SIR of brain tumours was 1.7 in offspring of affected parents; it was 2.0 in siblings and 9.4 in families with a parent and
sibling affected. For spinal tumours, the SIRs were much higher for offspring of early onset tumours, 14.0 for offspring of affected
parents and 22.7 for siblings. The SIRs for peripheral nerve tumours were 16.3 in offspring of affected parents, 27.7 in siblings and
943.9 in multiplex families.
CONCLUSION: The results of this population-based study on medically diagnosed tumours show site-, proband- and age-specific risks
for familial tumours, with implications for clinical genetic counselling and identification of the underlying genes.
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Some 90% of nervous system tumours are located in the brain
whereas spinal and peripheral nerve tumours account for the
remainder (Centre for Epidemiology, 2007). Recently large
epidemiological studies on nervous system cancer have been
carried out but a few environmental risk factors have consis-
tently been identified (Bondy et al, 2008). Therapeutic and
low-level irradiation, hereditary syndromes and family history
remain as the established risk factors of nervous system tumours
(Stewart and Kleihues, 2003; Hijiya et al, 2007; Maule et al,
2007; Hemminki et al, 2008a). Less than 3% of patients with
nervous system tumours have a first-degree family member
diagnosed by these neoplasms (Hemminki et al, 2008b). Because
of the low incidence and rarity of familial cancers many of the
published genetic epidemiological studies have not been able
to distinguish anatomic locations or tumour types with suffi-
cient numbers of cases (Goldgar et al, 1994; Hemminki et al,
1998, 2001a, 2009; Malmer et al, 1999, 2001, 2002; Paunu et al,
2002; Hemminki and Li, 2003; Blumenthal and Cannon-Albright,
2008). Although the data on familial risks in nervous system
cancer are overwhelmingly positive showing an effect, the
data from Iceland show no effects (Amundadottir et al, 2004).
By contrast, the data on childhood brain tumours has not
shown strong familial effects with some exceptions (Olsen et al,
1995; O’Neill et al, 2002; Searles Nielsen et al, 2008; Hemminki
et al, 2009).
To overcome the problems of small numbers of familial nervous
system tumours, we carried out a joint study in five Nordic
countries all of which have population records to assemble families
and nationwide cancer registries. Moreover, the incidence rates do
not appreciably differ between the Nordic countries, all rates
remaining in the interval 5.9–7.8 per 100000 for men and 4.6–6.5
per 100000 for women (IARC, 2002). Joint Nordic family studies
have been carried out before but they have focused on childhood
cancer because in many of the participating countries the family
linkages were possible only between parents and relatively young
offspring (Sankila et al, 1998; Olsen et al, 2001; Winther et al,
2001). In this landmark study we show that joint Nordic family
studies are feasible by extending the second generation at least to
mid age in all five countries and thus covering a population base of
25 million people. A histology-specific analysis was recently
reported on the Swedish and Norwegian data sets (Hemminki
et al, 2009). In this study also Danish, Finnish and Icelandic data
sets were included and a novel analysis distinguished tumours in
the brain, spinal cord and peripheral nerves. A total of 63307
patients with nervous system cancers were identified and among
them 851 in the offspring generation had a family history.
In addition to being the largest study yet conducted, the other
advantages include registered and compete family structures
and complete medically diagnosed cancers from nationwide
registries.
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The five Nordic countries have population registers through which
any offspring with a nervous system tumour can be identified
whose parents or siblings were also diagnosed with nervous system
tumour. With the exception of Iceland, sibships could only be
ascertained in the offspring generation.
Statistics Sweden maintains a Multigeneration Register that
covers offspring born after 1931 along with their parents. We have
linked this Register to the Swedish Cancer Registry (1958–2004) to
make the Family-Cancer Database (MigMed2) in year 2006 with a
total population of over 11.5 million individuals. In addition to the
native Swedes the Family-Cancer Database contains data on all
immigrants residing in Sweden. In the Database all data are
organised in child–mother–father triplets; the parents have been
registered at the time of birth of the child, allowing tracking of
biological parents. The completeness of cancer registration in the
1970s has been estimated to be over 95%, and is now considered to
be close to 100%. The percentage of cytologically or histologically
verified cases has been close to 100%. The Swedish Cancer
Registry is based on compulsory notification of cases. A four-digit
diagnostic code according to the International Classification of
Diseases, 7th revision according to the International Classification
of Diseases for Oncology, World Health Organization (WHO) was
combined with a three-digit pathological anatomic diagnosis
(PAD) code provided by the Cancer Registry. Cranial nerve
tumours were included among brain tumours. The Swedish data
included 34934 nervous system cancer patients. The follow-up was
from 1961 to 2004.
The Norwegian data source covers all people born in Norway
between 1900 and 2005, totalling 6.4 million individuals. Data on
familial relationships, birth, vital status and sex were collected
from the Central Population Register, which was linked to the
national Cancer Registry of Norway. Offspring linkage to parents
was almost complete for Norwegian-born offspring since 1954 and
available for foreign-born offspring from 1960. Likewise, informa-
tion on date of death and emigration was available from 1960.
The Norwegian data included 19317 nervous system cancer
patients. The follow-up was from 1953 to 2005.
The Danish proband population data, born between 1935 and
2003, and diagnosed with brain or spinal cord cancer between 1978
and 2003, were retrieved from the nationwide Danish Cancer
Registry. Malignant and benign tumours were included. Peripheral
nerve tumours, acoustic neurinomas and other cranial nerve
tumours were excluded because of variable reporting. First-degree
relatives were identified for probands by linkage to the Danish
Central Population Register, which provides data on birth, sex,
vital status and familial relationships in all the Danish population
since 1 April 1968. A Danish modified version of the International
Classification of Diseases, 7th revision according to the Interna-
tional Classification of Diseases for Oncology, WHO was used
to classify the cancers. Danish age-, sex- and period-specific
incidence rates of each type of cancer were used for person-years
calculation with follow-up period 1967–2003. The Danish data
included 7941 nervous system cancer patients.
The Icelandic Genealogy Database contains verified and updated
information on the genealogies of all Icelanders dating back to
birth year 1840. The database was constructed under the auspices
of the Genetical Committee of the University of Iceland, starting in
1965. It was created by linking between the 1910 census and the
Icelandic National Registry (founded in 1953), and then completed
for all Icelanders born after 1839 by adding information on the
period 1840–1910 from parish records and censuses. The database
has been the basis for numerous scientific investigations, for more
than three decades. From the Icelandic Cancer Registry, known to
cover more than 99% of all cancer diagnosed in Iceland, probands
of all ages and diagnosed with brain cancer between 1955 and 2005
were linked to the Genealogy Database to trace first-degree
relatives. A patient was kept as a proband, although he or she
was a relative in another family. Information was obtained on vital
status and gender. The follow-up period started in January 1955 or
at birth, whichever came first, and ended on 31 December 2005 or
at death. The Icelandic data included 1120 nervous system cancer
patients.
In Finland, the national population registration system at
Population Register Center includes links to parent for offspring
younger than 20 years in October 1973 when the links were first
created; also older offspring were linked to parents if they lived in
the parental address in 1973. Thus parents can be automatically
traced virtually for every person born in October 1953 or later.
Finnish Cancer Registry is known to cover practically all cancers
diagnosed in Finland. The Finnish data included 1370 nervous
system cancer patients. The follow-up was from 1953 to 2005.
Standardised incidence ratios (SIRs) were used to measure the
cancer risks for offspring according to occurrence of cancers in
their families. Standardised incidence ratios were calculated for
offspring whose parent, sibling or parent and sibling had the same,
concordant cancer, that is using parents or sibling as probands.
Follow-up was started for each offspring at birth, immigration or
1 January, of the country-specific year, stated above, whichever
came latest. Follow-up was terminated on diagnosis of first cancer,
death, emigration or the closing date of the study, 31 December
2003/2004/2005, depending on the country. When more than two
affected offspring were found in any family, they were counted as
independent event. Standardised incidence ratios were calculated
as the ratio of observed (O) to expected (E) number of cases. The
expected numbers were calculated from 5-year-age-, sex-, tumour
type- and period- (5-year bands) specific standardised incidence
rates for all offspring lacking a family history (Esteve et al, 1994).
Confidence intervals (95% CI) were calculated assuming a Poisson
distribution (Esteve et al, 1994). Risks for siblings were calculated
using the cohort method, described and discussed elsewhere
(Hemminki et al, 2001b). In this method, sibships of two or more
are included and all siblings contribute to cases and person years.
Families with multiple affected individuals are ascertained at
multiple times and they are not independent, leading to too
narrow CIs (approximately by a factor of 1.4, Hemminki et al,
2001b); no correction was carried out in this article.
RESULTS
The joint Nordic study results are shown in Table 1. Among 32347
offspring patients with nervous system cancer, 851 were familial
cases, thus accounting for 2.6% of all patients. Considering
additionally the parental probands, 1381 familial cases were
identified. Familial risks were calculated when probands presented
with any nervous system cancers. The SIRs were higher for siblings
than for offspring of parental probands, and they were highest
when both a parent and a sibling were probands (multiplex
families, SIR 7.85). Affected offspring in multiplex families
numbered 42, that is they accounted for 4.7% of the offspring
with familial nervous system tumours. When cases were
found in 0- to 19-year olds, the SIRs were higher than those in
older cases.
In Table 2, site-specific familial risks are shown in two age
groups (0–19 and 20þ years) and separately for a concordant
family history (brain–brain, spine–spine etc.) and a family history
of nervous system tumours. The Finnish data were not included in
this and later analysis because of the small number of cases. Brain
cancer accounted for 87.6% of all offspring cases and 93.7% of the
familial cases, spinal tumours accounted for 6.7% of all and 1.3%
of the familial cases, peripheral tumours accounted for 5.7% of
all and 6.0% of the familial cases. The early onset cases were a
minority of all cases at each anatomic site but among familial
spinal and peripheral nerve patients they were the majority.
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highest risk, followed by the spine and the brain. Young patients
had higher risks than the older ones, and multiplex families
(parent and sibling proband) showed higher risks than siblings or
offspring of affected parents. The SIR of brain tumours was 1.7 in
offspring of affected parents, 2.0 in siblings and 9.4 in multiplex
families. For spinal tumours, the SIRs were much higher for early
onset tumours, 14.0 for offspring of affected parents and 22.7
for siblings. The SIRs for peripheral nerve tumours were 16.3
in offspring of affected parents, 27.7 in siblings and 943.9 in
multiplex families. When the probands were diagnosed with
nervous system tumours, instead of those in concordant anatomic
sites, the SIRs for brain tumours increased but those for the other
sites decreased.
In Table 3, the SIRs for early and late onset tumours are
considered for cases and probands by concordant anatomic site
only. The early onset brain tumours were increased in offspring of
affected parents (4.79) and in siblings (6.06). The highest risk of
the study, SIR 2563, was observed for peripheral nerve tumours in
a single multiplex family.
DISCUSSION
We aimed at testing the feasibility of familial linkages for adult
cancers in all the Nordic countries, which would enable future
collaboration with global visibility in a current base population of
25 million. All the countries have nationwide cancer registries
started for more than half a century ago. Although with some
national features, particularly for Iceland with a genealogical
database, the basic linkage of family members was performed
through the personal identifier on which the national population
registers have assembled the family members. The age of the second
generation depended on the period when the personal identifier was
introduced, except for Iceland. It was introduced first in Sweden, in
the year 1947, and those who were 15 years at that time, that is born
in the year 1932, were linked to their parents; thus the highest
possible offspring age was 72 years in Sweden. There was no age
limit in Iceland whereas for the remaining Nordic countries, the
second generation aged up to 50s. Nervous system cancer was
selected for study because it is of relatively early onset and thus
many cases were recorded even in the second generation.
Table 1 Estimates of SIRs for familial risk of offspring nervous system tumours in the Nordic countries
Sweden, Norway, Denmark, Finland and Iceland
Parental proband Sibling proband Parent and sibling proband
Age of cases O SIR 95% CI O SIR 95% CI O SIR 95% CI No family history All
0–19 years 125 2.24 1.87 2.67 54 2.71 2.03 3.54 10 23.47 11.18 43.34 7401 7590
20+ years 384 1.58 1.42 1.74 246 1.85 1.63 2.10 32 11.80 8.06 16.67 24095 24757
All ages 509 1.70 1.56 1.86 300 1.97 1.75 2.20 42 13.38 9.64 18.10 31496 32347
Abbreviation: SIR¼standardised incidence ratio. SIR adjusted for age, sex and 5-year periods. Values given in bold indicate that 95% CI do not include 1.0.
Table 2 Estimates of SIRs for familial risk of early and late onset nervous system tumours in offspring
Sweden, Norway, Denmark and Iceland
SIR by concordant
family history
SIR by family history of cancer in
the nervous system
Parental
proband
Sibling
proband
Parent and
sibling proband
Parental
proband
Sibling
proband
Parent and
sibling proband
Subsite and
age in cases O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI Cases
Brain
0–19 years 67 1.7 1.3 2.1 35 2.7 1.9 3.7 — — 86 1.9 1.5 2.3 40 2.6 1.8 3.5 5 15.3 4.8 35.9 5751
20+ years 286 1.7 1.5 1.9 166 1.9 1.6 2.2 17 10.8 6.3 17.3 314 1.6 1.4 1.8 19.5 1.9 1.6 2.2 20 9.5 5.8 14.7 20991
All ages 353 1.7 1.5 1.8 201 2.0 1.7 2.3 17 9.4 5.5 15.1 400 1.7 1.5 1.8 235 2.0 1.7 2.2 25 10.3 6.7 15.2 26742
Spine
0–19 years 3 14.0 2.6 41.4 2 22.7 2.1 83.7 — — 14 3.6 2.0 6.1 4 3.0 0.8 7.6 — — 440
20+ years 1 1.4 0.0 8.2 2 4.2 0.4 15.5 — — 22 1.5 0.9 2.2 16 2.1 1.2 3.4 2 12.8 1.2 47.0 1590
All ages 4 4.4 1.1 11.3 4 7.1 1.8 18.4 — — 36 1.9 1.3 2.6 20 2.2 1.4 3.4 2 10.8 1.0 39.9 2030
Peripheral nerves
a
0–19 years 11 29.8 14.8 53.5 5 24.7 7.8 58.1 — — 15 2.5 1.4 4.1 8 3.8 1.6 7.6 3 63.0 11.9 186.6 685
20+ years 5 8.2 2.6 19.2 12 29.2 15.0 51.1 4 1816.7 472.5 4697.6 22 1.5 0.9 2.3 19 2.6 1.6 4.1 7 45.5 18.0 94.3 1037
All ages 16 16.3 9.3 26.6 17 27.7 16.1 44.4 4 943.9 245.5 2440.6 37 1.8 1.3 2.5 27 2.9 1.9 4.2 10 49.7 23.6 91.7 1722
Nervous system
0–19 years 118 2.1 1.8 2.6 54 2.9 2.2 3.8 8 20.4 8.7 40.5 6963
20+ years 375 1.6 1.4 1.7 240 1.9 1.6 2.1 29 11.1 7.4 16.0 24374
All ages 493 1.7 1.5 1.8 294 2.0 1.8 2.2 37 12.3 8.7 17.0 31337
Abbreviation: SIR¼standardised incidence ratio. SIR adjusted for age, sex and 5-year periods.
aDenmark not included. Values given in bold indicate that 95% CI do not
include 1.0.
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using three types of probands: ‘parent only’, ‘sibling only’ and
‘parent and sibling’ (multiplex families) to deduce the possible
inheritance and penetrance modes. Dominant and recessive effects
could be distinguished by a higher risk for siblings than for
offspring of affected parents. However, a similar effect would be
caused by environmental sharing in childhood, which could be
related to sibship size and order in a sibship as surrogates of
infections causes (Altieri et al, 2006). Another reason for a higher
risk among siblings than among offspring of affected parents could
be mortality in young patients before parenthood. Even though
survival in brain tumours has increased, over half of the patients
have died in 5 years; however, the survival depends on the tumour
type and it is better for benign tumours such as meningioma
compared with glioma (Talback et al, 2003). For brain and spinal
tumours, the excess sibling risk was found among early onset
cases, which may suggest a higher role for genetic effect than for
survival selection. Thus, even though for all the three anatomic
sites sibling risks exceeded those for offspring of affected parents
the data should be interpreted with caution. Multiplex families are,
however, likely to be due to high or moderate penetrance genetic
effects. In addition to the high penetrant genes causing syndro-
matic nervous system tumours (Kleihues and Cavenee, 2000),
a recent study identified five low-penetrant loci for glioma with
an estimated contribution of 7–14% to the familial clustering of
glioma (Shete et al, 2009).
Familial cases accounted for 2.6% of all patients in the offspring
generation, in line with previous estimates (Goldgar et al, 1994;
Hemminki et al, 2008b). Affected offspring in multiplex families
accounted for 4.7% of the offspring with familial nervous system
tumours, which indicates that most familial clusters are non-
syndromatic presenting with modest penetrance at most. Rare
cancer syndromes such as Li-Fraumeni, neurofibromatosis 1 and
2, von Hippel–Lindau, tuberous sclerosis, Turcot and Gorlin
would manifest in multiplex families (Kleihues and Cavenee, 2000;
Vogelstein and Kinzler, 2002). The very high risks for peripheral
nerve tumours in the multiplex families were probably due to
neurofibromatosis 1 and 2, which are often of early onset as in
this study. Gliomas also manifest in these syndromes and in
Li-Fraumeni syndrome and tuberous sclerosis.
Most of the nervous system cancers were located in the brain
(87.6%) and even larger percentage of concordant familial cases
were found there (93.7%). However, the concordant familial risks
were much higher for spinal and peripheral nerve tumours
compared with brain tumours. These high risks could partially
be explained by syndromatic cases in small families, discussed
above. The study showed that there is a clear familial risk in early
onset brain tumours both through parental and sibling probands,
and also when probands were diagnosed before age 20 years.
The present population-level data on medically diagnosed cases
from the five Nordic countries provide solid risk estimates for
familial nervous system tumours. These data should be useful for
the clinical setting by offering cancer patients and their relatives
unbiased estimates on and objective advice about familial cancer
(Hemminki and Eng, 2004). Second, these data should be useful in
the planning of gene identification efforts before the projects have
been initiated and in the estimation of their success after new
susceptibility genes have been identified (Hemminki et al, 2006).
To reach the ultimate goal of genetic understanding of nervous
system tumour aetiology, we need to account the detected genes
for all of the genetic familial aggregation of this disease.
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